Angus Cameron is a Senior Director at The Weinberg Group. Mr. Cameron has over 20 years of experience in human pharmaceutical registration. He has advised companies on all aspects of drug development, from early pre-clinical testing through Phases I to III in man and marketing authorisation applications. Therapeutic areas include analgesics, cancer therapies, recombinant DNA products, monoclonal antibodies, biologically derived products, “borderline” products and POM to P switches. He has extensive experience in clinical trial approval work across the European Union.